Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 206 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Ticagrelor: The first approved reversible oral antiplatelet agent

Goel Divya

Year : 2013| Volume: 3| Issue : 1 | Page no: 19-21

   This article has been cited by
1 Untargeted metabolomics reveals the mechanism of quercetin enhancing the bioavailability of ticagrelor
Weijie Zhang,Yaxin Sun,Shuangyan Wei,Bo Wei,Xia Xu,Youcai Tang
Biomedical Chromatography. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia
Josh Sun,Satoshi Uchiyama,Joshua Olson,Yosuke Morodomi,Ingrid Cornax,Nao Ando,Yohei Kohno,May M. T. Kyaw,Bernice Aguilar,Nina M. Haste,Sachiko Kanaji,Taisuke Kanaji,Warren E. Rose,George Sakoulas,Jamey D. Marth,Victor Nizet
Science Translational Medicine. 2021; 13(586): eabd6737
[Pubmed]  [Google Scholar] [DOI]
3 Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study
Heba Elmansi,Sahar Zayed,Fathalla Belal
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2020; 242: 118722
[Pubmed]  [Google Scholar] [DOI]
4 Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study
Hua Yan,Xieraili Tiemuerniyazi,Yangwu Song,Fei Xu,Wei Feng
Journal of Cardiothoracic Surgery. 2020; 15(1)
[Pubmed]  [Google Scholar] [DOI]
5 Acetylcholine Inhibits Platelet Activation
John A. Bennett,Sara K. Ture,Rachel A. Schmidt,Michael A. Mastrangelo,Scott J. Cameron,Lara E. Terry,David I. Yule,Craig N. Morrell,Charles J. Lowenstein
Journal of Pharmacology and Experimental Therapeutics. 2019; 369(2): 182
[Pubmed]  [Google Scholar] [DOI]
6 Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic
Qian Xiang,Xiaocong Pang,Zhenming Liu,Guoping Yang,Weikang Tao,Qi Pei,Yimin Cui
Pharmacology & Therapeutics. 2019; : 107393
[Pubmed]  [Google Scholar] [DOI]
7 The P2Y12 Receptor Antagonist Ticagrelor Reduces Lysosomal pH and Autofluorescence in Retinal Pigmented Epithelial Cells From the ABCA4-/- Mouse Model of Retinal Degeneration
Wennan Lu,Néstor M. Gómez,Jason C. Lim,Sonia Guha,Ann O’Brien-Jenkins,Erin E. Coffey,Keith E. Campagno,Stuart A. McCaughey,Alan M. Laties,Leif G. Carlsson,Claire H. Mitchell
Frontiers in Pharmacology. 2018; 9
[Pubmed]  [Google Scholar] [DOI]
8 The effects of signal transducer and activator of transcription three mutations on human platelets
Floor E. Aleva,Frank L. van de Veerdonk,Yang Li,Rahajeng N. Tunjungputri,Sami Simons,Philip G. De Groot,Mihai M. Netea,Yvonne F. Heijdra,Quirijn de Mast,André J.A.M. van der Ven
Platelets. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
9 The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis
Ying Xue,Zhi-wei Feng,Xiao-ye Li,Zi-heng Hu,Qing Xu,Zi Wang,Jia-hui Cheng,Hong-tao Shi,Qi-bing Wang,Hong-yi Wu,Xiang-Qun Xie,Qian-zhou Lv
Acta Pharmacologica Sinica. 2017;
[Pubmed]  [Google Scholar] [DOI]


Read this article